Monday, 23 July 2018 - 2:45
  • it
  • de
  • en
  • fr

CTL019

EMA: Novartis submits MAA for CAR-T therapy Kymriah

Novartis announced today that that it has submitted a MAA (Marketing Authorization Application) to EMA for CTL019 (tisagenlecleucel) for two different indications. Indeed, the application refers both to the treatment of children and young adults with B-cell ALL (acute lymphoblastic…